Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.42 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1306565 | 1.00 | IGF1R (0.42) | IGF1RHMOX1CYP3A4TSHRMEN1 | |
| SCHEMBL1305581 | 1.00 | IGF1R (0.42) | IGF1RHMOX1CYP3A4TSHRMEN1 | |
| SCHEMBL17438169 | 0.87 | TSHR (0.48) | CYP3A4TSHRHTR3A | |
| SCHEMBL2368070 | 0.82 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL1986354 | 0.82 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL241160 | 0.82 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL16070705 | 0.81 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL16070654 | 0.81 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL3175979 | 0.81 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL3839205 | 0.81 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292417-A | Process for producing carboxylic acid | 赣南医学院 | 2021-08-24 | — | — | CN | claimed |
| CN-111171085-A | Rhamnose donor protected by orthocarbonate, and preparation method and application thereof | 山东大学 | 2020-05-19 | — | — | CN | claimed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-118340754-B | Compound for treating heart failure and related diseases and application thereof | 源道医药(苏州)有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119490387-A | Compounds for the treatment of pain-related diseases | 源道医药(苏州)有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2025021217-A1 | QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | WO | disclosed |
| CN-118340754-A | Compound for treating heart failure and related diseases and application thereof | 源道医药(苏州)有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240166609-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2024-05-23 | — | — | US | disclosed |
| WO-2024082872-A1 | PAK4 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都海博为药业有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-112638985-B | Fluorine-containing aromatic polymer and method for producing same | 大金工业株式会社 | 2024-03-15 | — | — | CN | disclosed |
| US-20030176528-A1 | Photosensitive resin composition, dry film, and workpiece using the same | MITSUI CHEMICALS, INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030032806-A1 | Oxidation of carbon-boron bonds | CAI WEILING (US) | 2003-02-13 | — | — | US | disclosed |
| US-20020169206-A1 | Substituted biphenyl compounds for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-11-14 | — | — | US | disclosed |
| US-20020049352-A1 | Oxidation of carbon-boron bonds | CAI WEILING (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1167329-A2 | Oxidation of carbon-boron bonds | Pfizer Products Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-0794942-B1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2000-05-31 | — | — | EP | disclosed |
| US-6043235-A | 11β-aryl-17, 17-spirothiolane-substituted steroids | RESEARCH TRIANGLE INSTITUTE (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0794942-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016934-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169206-A1 | Substituted biphenyl compounds for the treatment of inflammation | AHR, ARNT, GPBAR1 | IGF1R 1701/4885HMOX1 47/4885CYP3A4 206/4885 |
| US-20240166609-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, MPO, RPN2 | IGF1R 4070/4885HMOX1 365/4885CYP3A4 3548/4885 |
| US-20030032806-A1 | Oxidation of carbon-boron bonds | CYBB, FOSB, SCO2 | IGF1R 2935/4885HMOX1 128/4885CYP3A4 989/4885 |
| US-20020049352-A1 | Oxidation of carbon-boron bonds | CYBB, FOSB, SCO2 | IGF1R 2935/4885HMOX1 128/4885CYP3A4 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.